Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants

Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (mAbs), 58G6, 510A5 and 13G9, with high neutralizing...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tingting, Han, Xiaojian, Gu, Chenjian, Guo, Hangtian, Zhang, Huajun, Wang, Yingming, Hu, Chao, Wang, Kai, Liu, Fengjiang, Luo, Feiyang, Zhang, Yanan, Hu, Jie, Wang, Wang, Li, Shenglong, Hao, Yanan, Shen, Meiying, Huang, Jingjing, Long, Yingyi, Song, Shuyi, Wu, Ruixin, Mu, Song, Chen, Qian, Gao, Fengxia, Wang, Jianwei, Long, Shunhua, Li, Luo, Wu, Yang, Gao, Yan, Xu, Wei, Cai, Xia, Qu, Di, Zhang, Zherui, Zhang, Hongqing, Li, Na, Gao, Qingzhu, Zhang, Guiji, He, Changlong, Wang, Wei, Ji, Xiaoyun, Tang, Ni, Yuan, Zhenghong, Xie, Youhua, Yang, Haitao, Zhang, Bo, Huang, Ailong, Jin, Aishun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563728/
https://www.ncbi.nlm.nih.gov/pubmed/34728625
http://dx.doi.org/10.1038/s41467-021-26539-7
Descripción
Sumario:Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (mAbs), 58G6, 510A5 and 13G9, with high neutralizing potency blocking authentic SARS-CoV-2 virus display remarkable efficacy against authentic B.1.351 virus. Surprisingly, structural analysis has revealed that 58G6 and 13G9 both recognize the steric region S(470–495) on the RBD, overlapping the E484K mutation presented in B.1.351. Also, 58G6 directly binds to another region S(450–458) in the RBD. Significantly, 58G6 and 510A5 both demonstrate prophylactic efficacy against authentic SARS-CoV-2 and B.1.351 viruses in the transgenic mice expressing human ACE2 (hACE2), protecting weight loss and reducing virus loads. Together, we have evidenced 2 potent neutralizing Abs with unique mechanism targeting authentic SARS-CoV-2 mutants, which can be promising candidates to fulfill the urgent needs for the prolonged COVID-19 pandemic.

Ejemplares similares